Fresh Tracks Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 7.94 million compared to USD 0.486 million a year ago. Net income was USD 1.91 million compared to net loss of USD 6.02 million a year ago. Basic earnings per share from continuing operations was USD 0.32 compared to basic loss per share from continuing operations of USD 2.07 a year ago.
For the nine months, revenue was USD 8.01 million compared to USD 4.89 million a year ago. Net loss was USD 4.46 million compared to USD 16.58 million a year ago. Basic loss per share from continuing operations was USD 0.86 compared to USD 6.05 a year ago.